In addition, a phase II clinical trial by Porter et al. (2024) evaluated the combination of MIRV and pembrolizumab in 16 patients with recurrent or persistent, MSS/pMMR, FRα-positive endometrial cancer (EC). This evidence concerns the gene FOLR1 and endometrial cancer.